جميع الدراسات
التوظيفالمرحلة 4تدخلي

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

This research trial, called TripleTRE, is looking at the best way to start treatment for people with a condition called pulmonary arterial hypertension (PAH), which causes high blood pressure in the lungs. It compares two different treatment approaches for adult patients who are newly diagnosed or haven't been treated for PAH before. One group receives a combination of three medicines: two oral tablets and one medicine (treprostinil) given by injection. The other group receives two oral tablets, which is a common starting treatment. The main goal is to see which treatment helps more patients achieve a 'low risk' status, meaning their condition is better managed. This study will help doctors improve care for PAH patients.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 4
الراعي
AOP Orphan Pharmaceuticals AG
الهدف من التسجيل
110
ابدأ
06 Dec 2023
التاريخ المتوقع للانتهاء
30 يونيو 2027

ما هو موضوع هذه الدراسة؟

Pulmonary arterial hypertension, or PAH, is a serious condition where the blood pressure in the arteries leading to your lungs becomes too high. This makes your heart work much harder and can lead to serious health problems. Doctors are always looking for the best ways to treat PAH and help patients live better lives. This study, called TripleTRE, is exploring whether starting treatment with a combination of three medicines might be more effective than starting with two for certain patients.

Currently, many patients with PAH start treatment with two oral medicines. These medicines work in different ways to relax blood vessels in the lungs and lower blood pressure. TripleTRE is investigating whether adding a third medicine, treprostinil (which is given by injection), right from the start can lead to better outcomes, especially for patients with a higher risk level or more severe symptoms.

This trial is for adults with specific types of PAH who are newly diagnosed or haven't received PAH treatment in the past three months. Researchers will carefully monitor how patients respond to their assigned treatment over several months to understand the safety and effectiveness of each approach. The results could help doctors decide the best way to begin treatment for future PAH patients.

النقاط الرئيسية

  • Compares two starting treatments for PAH: two pills vs. two pills plus an injected medicine.
  • Aims to find out which approach leads to better health for PAH patients.
  • Involves adults (18-70) with specific types of newly diagnosed or untreated PAH.
  • Participation lasts between 6 months and a year with regular hospital visits.
  • You will know which treatment you are receiving (it's 'open-label').

من قد يكون مؤهلاً؟

This study is looking for adults aged between 18 and 70 years old who have just been diagnosed with certain types of pulmonary arterial hypertension (PAH) or haven't been treated for it in the last three months. These types include PAH that doesn't have a clear cause (idiopathic), PAH that runs in families (hereditary), PAH caused by medicines or toxins, PAH linked to connective tissue diseases, or PAH with a repaired heart defect from birth.

You might be able to join if your PAH is considered 'intermediate-high risk' or 'intermediate-low risk' but with some severe signs of how your heart and lungs are working. Doctors will do some tests, including a special heart catheterisation, to check your heart and lung pressures and confirm your diagnosis.

However, you won't be able to join if you have certain other types of PAH (like those linked to schistosomiasis, HIV, liver problems, or a widespread skin condition called diffuse systemic sclerosis) or if your heart defect from birth hasn't been fixed. You also can't participate if you've already had PAH-specific treatment recently, if your PAH responds to certain tablets called calcium channel blockers, or if you have certain other lung or heart conditions.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. هل عمرك بين 18 و 70 سنة؟
  2. Have you been diagnosed with PAH recently, or have you not taken PAH medicines in the last 3 months?
  3. Is your PAH one of these types: idiopathic, hereditary, drug/toxin-induced, associated with connective tissue disease, or with corrected congenital heart disease?
  4. Are you able to use reliable contraception if you're a woman who could become pregnant?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part in the TripleTRE study, you'll be randomly assigned to one of two treatment groups, like flipping a coin. You'll receive either two oral medications or the same two oral medications along with treprostinil, which is given by an injection. All medicines will be started within three weeks of joining the study. You'll have regular visits to the hospital for check-ups, tests, and to monitor how you're feeling and how the treatment is working. This will include blood tests, heart and lung function tests, and possibly repeats of the heart catheterisation. The study will follow your progress for about 24 to 48 weeks, which is roughly between six months and a year.

المخاطر والفوائد المحتملة

Participating in a study like TripleTRE means you'll receive close medical attention and access to potentially effective treatments for your PAH. While the goal is to find better treatments, there's no guarantee that the treatment you receive will improve your condition, and side effects are possible with any medication. The additional treprostinil in one group is given by injection, which has its own potential risks like injection site reactions. The research team will explain all known risks of the medicines used. You have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (19)

  • Ordensklinikum Linz
    الرمز البريدي المؤكد
    لينز، النمسا· التوظيف
  • Medical University Vienna
    الرمز البريدي المؤكد
    فيينا، النمسا· التوظيف
  • Fakultní Nemocnice Olomouc
    الرمز البريدي المؤكد
    Olomouc, Czechia· لم يبدأ التوظيف بعد
  • Všeobecná fakultní nemocnice v Praze
    الرمز البريدي المؤكد
    براغ، التشيك· لم يبدأ التوظيف بعد
  • Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris
    الرمز البريدي المؤكد
    باريس، فرنسا· لم يبدأ التوظيف بعد
  • Hôpitaux Universitaires de Strasbourg
    الرمز البريدي المؤكد
    ستراسبورغ، فرنسا· لم يبدأ التوظيف بعد
  • DRK Kliniken Berlin Westend
    الرمز البريدي المؤكد
    برلين، ألمانيا· لم يبدأ التوظيف بعد
  • University Hospital Carl Gustav Carus of Technical University Dresden
    الرمز البريدي المؤكد
    درسدن، ألمانيا· لم يبدأ التوظيف بعد
  • Universitätsmedizin Greifswald
    الرمز البريدي المؤكد
    Greifswald, Germany· لم يبدأ التوظيف بعد
  • Gottsegen National Cardiovascular lnstitute
    الرمز البريدي المؤكد
    Budapest, Hungary· لم يبدأ التوظيف بعد
  • Medical University of Szeged
    الرمز البريدي المؤكد
    Szeged, Hungary· لم يبدأ التوظيف بعد
  • Sapienza University of Rome
    الرمز البريدي المؤكد
    روما، إيطاليا· التوظيف

أسئلة شائعة

What is PAH?

PAH stands for pulmonary arterial hypertension. It's a condition where the blood pressure in the arteries that carry blood from your heart to your lungs is too high, making your heart work harder.

ما نوع الأدوية التي يتم اختبارها؟

The study is testing combinations of medicines. Both groups will get two oral medicines. One group will also get an additional medicine called treprostinil, which is given by injection.

كم ستستغرق الدراسة بالنسبة لي؟

If you join the study, your treatment and monitoring will last for approximately 6 to 12 months (24 to 48 weeks).

هل سأعرف أي علاج سأحصل عليه؟

Yes, this is an 'open-label' study, which means both you and your doctor will know whether you are receiving the two oral medicines or the three-medicine combination.

هل يجب علي الدفع للمشاركة في الدراسة؟

No, all study-related treatments and tests are provided at no cost to you.

كيفية معرفة المزيد

Clinical Project Manager

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "Initial Triple Therapy Including Parenteral Treprostinil vs … "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.